Biosimilars Forum Opposes Current CMS Rule That Would Adversely Affect Biosimilars Development in the U.S.; Submits Comments on Appropriate Biosimilar Reimbursement Policy

WASHINGTON, Sept. 14, 2017 /PRNewswire/ -- Recently, the Biosimilars Forum submitted comments on the Centers for Medicare & Medicaid Services' (CMS) proposed Medicare Physician Fee Schedule (MPFS) regarding biosimilar reimbursement policy that was finalized in 2016. As...